Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Oramed Pharmaceuticals Inc. (ORMP)

Bicycle Therapeutics PLC Sponsored ADR and Oramed Pharmaceuticals Inc. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Oramed Pharmaceuticals Inc. are of similar size ($199.4M and $199.3M). Bicycle Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Oramed Pharmaceuticals Inc. trades at 1.1×. Oramed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 347.8% against 217.4%. Oramed Pharmaceuticals Inc. has the higher net margin (0.00% vs −311.1%) and the higher return on invested capital (−3.40% vs −64,747.5%). Across the 17 metrics below, Oramed Pharmaceuticals Inc. leads on 10 and Bicycle Therapeutics PLC Sponsored ADR on 7.

Valuation

Metric BCYC ORMP Biotechnology median
P/E n/m 1.12 7.88
P/S 4.21 48.28 11.47
P/B 0.50 0.61 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 1.13 n/m 0.74
EV/Sales (3.78) 35.69 10.73
Earnings yield (73.98%) 89.43% (28.84%)
Free cash flow yield (80.86%) (2.69%) (23.03%)

Profitability

Metric BCYC ORMP Biotechnology median
Gross margin 100.00% 32.31% 65.16%
Operating margin (343.60%) 0.00% 0.00%
Net margin (311.11%) 0.00% 0.00%
Free cash flow margin (340.29%) 0.00% 0.00%
Return on equity (32.30%) 73.90% (57.72%)
Return on assets (26.47%) 65.52% (49.22%)
Return on invested capital (64,747.54%) (3.40%) 0.00%

Growth

Metric BCYC ORMP Biotechnology median
Revenue growth (TTM) 217.44% 347.77% 5.64%
EPS growth (last fiscal year) (8.97%) 412.50% —
Revenue growth, 5-year CAGR 47.52% (5.85%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC ORMP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.08 4.98 4.73
Net debt to EBITDA 2.61 8.41 0.96

Dividend

Metric BCYC ORMP Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCYC ORMP Biotechnology median
Market cap 199.41m 199.25m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack